Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...

A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...

SC lawmakers advanced a bill that would require a disclaimer for COVID-19 vaccinations. Physicians have broadly encouraged ...

Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE , more than five years after both ...

Pfizer’s respiratory syncytial virus vaccine was more than 90% effective among older adults during the first season it was available, including among those with underlying conditions or severe disease ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.

Pfizer announced Friday that it would submit a request to the FDA Friday for its COVID-19 vaccine to be granted Emergency Use Authorization. Earlier this week, Pfizer said that a final analysis of ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...